Specialising in Multiple Myeloma Trials

15+ Years of experience in Hematology Research bringing real intelligence to the table. We have first hand seen how your therapies have ignited hope in thousands of patients. We understand how hard they fight every single day, and we know your vision to accelerate progress and bring more options to them. Your cause fuels our commitment, and together we can turn your vision into reality!

Trusted Global Partner for Multiple Myeloma Trials

15+ Years of Collaborative work

Creating trusted, long lasting relationships with renowned KOLs and NFPs

Combining our experience with an agile approach and continuous support throughout the whole lifecycle process

Pre-Clinical Trials

Late Phase Trials

Experience Across the Continuum of Care

Newly Diagnosed Multiple Myeloma

Pioneering combination therapies for transplant-eligible patients, from induction to post-ASCT maintenance. Extending care to transplant-ineligible populations with customized frontline regimens.

Relapsed/Refractory Multiple Myeloma

Supporting the next-gen combinations for patients after two or more prior lines of therapy. Integrating novel agents to overcome resistance and reshape treatment horizons.

Expertise with Elderly & Frail Populations

Clinical trials in elderly multiple myeloma patients must balance efficacy with tolerability, considering frailty, comorbidities, and polypharmacy. We’ve helped navigate protocol design and execution in elderly patients, including those with significant comorbidities..

Renal-Impaired and Dialysis-Dependent Cohorts

We have extensive experience with complex renal impairment trials which included enrolling participants on hemodialysis. Our cross-functional teams have a deep understanding on the pharmacokinetic considerations, specialized sample handling, and regulatory nuances these studies demand.

line

Research footprint spanning every major therapeutic category in Multiple Myeloma

Bispecific T-cell Engagers

Antibody-Drug Conjugates (ADCs)

Monoclonal Antibodies

Proteasome Inhibitors (PIs)

Immunomodulatory Drugs (IMiDs)

Why Sponsors
trust us for Multiple
Myeloma Trials?

Patient Recruitment and Retention

Deployed pre-screening tools and outreach programs through global networks. Leveraging partnerships to meet regulatory expectations for diversity and real-world representation.

Regulatory Diversity Across Regions

Access to local regulatory experts with centralized oversight to manage region to navigate region specific regulations and fastrack approvals

Global Operational Scale and Logistics

Managing study-specific logistical plans, sample management protocols & IMP supply chain across Europe, North America, South America Asia-Pacific and Australia regions

Site Readiness and Protocol Compliance

Tailored site-level training and deploying study-specific digital tools to ensure centralised consistency and manage site-level performance.

Advanced Data Management

Produced high-quality, inspection-ready GCP compliant datasets after coordinating high-volume data for Multiple Myeloma trials, including MRD, PK/PD, safety, and QoL endpoints.